Luis A. Carvajal
YOU?
Author Swipe
View article: New Pathogenic Variant in the GLI3 Gene in the First Colombian Patient Associated With Pallister‐Hall Syndrome: A Clinical Report
New Pathogenic Variant in the GLI3 Gene in the First Colombian Patient Associated With Pallister‐Hall Syndrome: A Clinical Report Open
Background Pallister‐Hall syndrome (PHS) is an extremely rare genetic disorder. It presents as a polymalformative syndrome affecting craniofacial structures, the central nervous system, limbs, various internal organs, and the endocrine sys…
View article: A pooled analysis of 3 large multicenter trials confirms a survival advantage for <i>NPM1</i> <sup>mut</sup> AML in MRD <sup>neg</sup> remission after intensive induction
A pooled analysis of 3 large multicenter trials confirms a survival advantage for <i>NPM1</i> <sup>mut</sup> AML in MRD <sup>neg</sup> remission after intensive induction Open
View article: Botanical Characterization and Herbarium Specimens of Mangifera Species
Botanical Characterization and Herbarium Specimens of Mangifera Species Open
Mangifera spp. belongs to the Anacardiaceae family. Twenty-two members of this genus have been collected at different living collections in Florida, including USDA Chapman Field–Subtropical Horticulture Research Station, the University of …
View article: Germinal pathogenic CHEK2, novel APC and somatic JAK2V617F variants in a young patient with colorectal cancer, atypical leukemia, cerebral tumour and aggressive course
Germinal pathogenic CHEK2, novel APC and somatic JAK2V617F variants in a young patient with colorectal cancer, atypical leukemia, cerebral tumour and aggressive course Open
Higher CHEK2 and JAK2 expression have been correlated with better survival among patients with rectal adenocarcinoma, lung squamous cell carcinoma, breast cancer, ovarian cancer and several other cancer types. It has been suggested that ge…
View article: PB1889: KB-LANRA 1001: A PHASE 1B/2 STUDY ON SAFETY, PK, PD, AND PRELIMINARY EFFICACY OF THE SELECTIVE SYK INHIBITOR LANRAPLENIB IN COMBINATION WITH THE FLT3 INHIBITOR GILTERITINIB, IN FLT3-MUTATED R/R AML
PB1889: KB-LANRA 1001: A PHASE 1B/2 STUDY ON SAFETY, PK, PD, AND PRELIMINARY EFFICACY OF THE SELECTIVE SYK INHIBITOR LANRAPLENIB IN COMBINATION WITH THE FLT3 INHIBITOR GILTERITINIB, IN FLT3-MUTATED R/R AML Open
Topic: 4. Acute myeloid leukemia - Clinical Background: In acute myeloid leukemia (AML), Spleen Tyrosine Kinase (SYK) serves as a relay to an oncogenic transcriptional regulatory network (TRN) linked to HOXA9 and MEIS1 and, as such, helps …
View article: Discovery of Sulanemadlin (ALRN-6924), the First Cell-Permeating, Stabilized α-Helical Peptide in Clinical Development
Discovery of Sulanemadlin (ALRN-6924), the First Cell-Permeating, Stabilized α-Helical Peptide in Clinical Development Open
We report the discovery of sulanemadlin (ALRN-6924), the first cell-permeating, stabilized α-helical peptide to enter clinical trials. ALRN-6924 is a "stapled peptide" that mimics the N-terminal domain of the p53 tumor suppressor protein. …
View article: All Supplementary Figures from Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity
All Supplementary Figures from Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity Open
All Supplementary Figures
View article: Data from p53 Promotes Cell Survival due to the Reversibility of Its Cell-Cycle Checkpoints
Data from p53 Promotes Cell Survival due to the Reversibility of Its Cell-Cycle Checkpoints Open
The tumor suppressor p53 (TP53) has a well-studied role in triggering cell-cycle checkpoint in response to DNA damage. Previous studies have suggested that functional p53 enhances chemosensitivity. In contrast, data are presented to show t…
View article: Data from Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity
Data from Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity Open
The repression of repetitive elements is an important facet of p53's function as a guardian of the genome. Paradoxically, we found that p53 activated by MDM2 inhibitors induced the expression of endogenous retroviruses (ERV) via increased …
View article: Data from Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity
Data from Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity Open
The repression of repetitive elements is an important facet of p53's function as a guardian of the genome. Paradoxically, we found that p53 activated by MDM2 inhibitors induced the expression of endogenous retroviruses (ERV) via increased …
View article: Supplementary References from Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity
Supplementary References from Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity Open
References for supplementary methods file
View article: Supplemental Material from p53 Promotes Cell Survival due to the Reversibility of Its Cell-Cycle Checkpoints
Supplemental Material from p53 Promotes Cell Survival due to the Reversibility of Its Cell-Cycle Checkpoints Open
Supplemental Material. Supplemental Figure S1. A: Doxorubicin treatment leads to the concentration-dependent induction of p53 and p21 in parental U2OS cells. U2OS cells were treated with doxorubicin at concentrations ranging from 0.05 μg/m…
View article: Supplementary Table S1 from Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity
Supplementary Table S1 from Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity Open
P53 CHIP-SEQ
View article: Supplementary Table S2 from Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity
Supplementary Table S2 from Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity Open
Raw data for FACs profiling of immune cells on CT26
View article: Supplementary Table S3 from Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity
Supplementary Table S3 from Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity Open
Primers, siRNAs and CRISPR guide RNAs
View article: Supplemental Material from p53 Promotes Cell Survival due to the Reversibility of Its Cell-Cycle Checkpoints
Supplemental Material from p53 Promotes Cell Survival due to the Reversibility of Its Cell-Cycle Checkpoints Open
Supplemental Material. Supplemental Figure S1. A: Doxorubicin treatment leads to the concentration-dependent induction of p53 and p21 in parental U2OS cells. U2OS cells were treated with doxorubicin at concentrations ranging from 0.05 μg/m…
View article: Data from p53 Promotes Cell Survival due to the Reversibility of Its Cell-Cycle Checkpoints
Data from p53 Promotes Cell Survival due to the Reversibility of Its Cell-Cycle Checkpoints Open
The tumor suppressor p53 (TP53) has a well-studied role in triggering cell-cycle checkpoint in response to DNA damage. Previous studies have suggested that functional p53 enhances chemosensitivity. In contrast, data are presented to show t…
View article: Supplementary Methods from Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity
Supplementary Methods from Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity Open
Supplementary Methods
View article: Supplementary Table S1 from Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity
Supplementary Table S1 from Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity Open
P53 CHIP-SEQ
View article: All Supplementary Figures from Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity
All Supplementary Figures from Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity Open
All Supplementary Figures
View article: Supplementary Methods from Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity
Supplementary Methods from Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity Open
Supplementary Methods
View article: Supplementary Table S2 from Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity
Supplementary Table S2 from Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity Open
Raw data for FACs profiling of immune cells on CT26
View article: Supplementary References from Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity
Supplementary References from Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity Open
References for supplementary methods file
View article: Supplementary Table S3 from Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity
Supplementary Table S3 from Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity Open
Primers, siRNAs and CRISPR guide RNAs
View article: Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity
Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity Open
The repression of repetitive elements is an important facet of p53's function as a guardian of the genome. Paradoxically, we found that p53 activated by MDM2 inhibitors induced the expression of endogenous retroviruses (ERV) via increased …
View article: MDMX acts as a pervasive preleukemic-to-acute myeloid leukemia transition mechanism
MDMX acts as a pervasive preleukemic-to-acute myeloid leukemia transition mechanism Open
View article: First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models
First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models Open
Background MDM2/MDMX proteins are frequently elevated in hormone receptor-positive (ER+) breast cancer. We sought to determine the antitumor efficacy of the combination of ALRN-6924, a dual inhibitor of MDM2/MDMX, with chemotherapy in ER+ …
View article: Infection with Helicobacter Pylori Presenting the vacA s2m2 haplotype is Strongly Associated with Protection Against Gastric Cancer
Infection with Helicobacter Pylori Presenting the vacA s2m2 haplotype is Strongly Associated with Protection Against Gastric Cancer Open
Background: Infection with Helicobacter pylori is recognized as the main risk factor for gastric cancer (GC); the clinical outcome of this infection is variable and partially depends on the virulence of the infective strain. This study cha…
View article: 473 Mavrilimumab, a human monoclonal antibody targeting GM-CSFRα, inhibits polarization to myeloid-derived suppressor cells (MDSCs) that express PD-L1 and restores T-cell proliferation in vitro
473 Mavrilimumab, a human monoclonal antibody targeting GM-CSFRα, inhibits polarization to myeloid-derived suppressor cells (MDSCs) that express PD-L1 and restores T-cell proliferation in vitro Open
Background Myeloid-derived suppressor cells (MDSCs) accumulate in the blood and tumor microenvironment (TME) and suppress anti-tumor immune responses.1 Cancer cells express the granulocyte-macrophage colony-stimulating factor (G…
View article: Cáncer de mama en seis familias del Tolima y el Huila: mutación BRCA1 3450del4
Cáncer de mama en seis familias del Tolima y el Huila: mutación BRCA1 3450del4 Open
Introducción. El cáncer de mama es un problema mundial de salud pública; entre el 5 y el 10 % de los casos presentan agregación familiar, lo que se explicaría por la presencia de mutaciones en genes de alto riesgo como el BRCA1 y el BRCA2.…